For patients
Oncodetect™ Molecular Residual Disease test

Clear and accurate results to help you stay a step ahead of your cancer

The Oncodetect Molecular Residual Disease (MRD) test looks for tiny fragments of cancer DNA in your blood and can detect cancer recurrence more than 2 years earlier than traditional cancer surveillance methods.1
A woman smiling and looking into the distance, with an orange circle around her head and shoulders.

Outcome

Detects fragments of DNA from your tumor to help you understand your risk of recurrence and monitor response to therapy or surgery.1

Is this test right for you?

The Oncodetect MRD test is for patients who have been diagnosed with solid cancers.*

Sample type

Initial test analyzes your blood, along with tumor tissue from your surgery or biopsy. Monitoring tests require only a blood sample.
Five women in a forest setting, wearing colorful clothing and smiling at each other.
Answering your biggest questions

Is my cancer gone? Is it responding to treatment? Could it come back?

You are one-of-a-kind — and so is your tumor. That’s why the Oncodetect MRD test looks for circulating tumor DNA (ctDNA) shed by your specific tumor. The results can help you and your health care provider make more informed decisions about your treatment path.

Detect and measure ctDNA levels to see if your cancer is gone after surgery1,2

A doctor showing a patient test results on a tablet.

Monitor response to surgery or adjuvant therapy, such as chemotherapy1,2

A woman in a head wrap walking through a hospital hallway, bending down to kiss a young girl on the cheek.



Understand if you are at a higher risk for your cancer coming back1,2

Two women standing on a beach smiling, one holding a young child.

Is this test right for me?

If you’ve been diagnosed with a solid cancer,* the Oncodetect MRD test can help guide chemotherapy decisions, detect signs of recurrence, and monitor your response to therapy.1,2 Read our helpful discussion guide for more details, including questions you may want to ask your oncologist.

Will insurance cover my test?

Exact Sciences believes everyone should be able to make confident, informed decisions about their cancer treatment. Our team is here to help you understand and navigate the insurance and billing process, and can assist with prior authorizations, billing insurance, appealing denied claims, and providing flexible payment options when necessary.

The Oncodetect MRD test is covered by Medicare for patients with stage II, III, and resectable stage IV colorectal cancer.† Medicare FFS patients who meet the coverage criteria will have $0 financial responsibility.

Exact Sciences Patient Assistance Program

Exact Sciences believes that everyone should have the opportunity to be as healthy as possible, no matter who they are, where they live, or how much money they make.

We’ll work with patients to help them understand their coverage and payment options, including those who are uninsured or underinsured. Our estimator tool can help patients understand if they qualify for assistance.‡

A doctor looking at the patient assistance calculator on a laptop.

Insights to help you plan your next steps with confidence

The Oncodetect MRD test is highly sensitive, so it’s able to detect even small fragments of ctDNA shed into the bloodstream from your tumor.1 Adding it to your surveillance plan can help you and your doctor make more timely treatment decisions.

Earlier answers

MRD testing can detect evidence of cancer up to 2 years earlier than imaging, giving you more time to plan your treatment path.1
Two men playing chess.

Personalized results

By tracking up to 200 gene variants specific to your tumor, the Oncodetect MRD test grants more opportunities to detect ctDNA in the blood.1,3
Man and woman embracing and smiling.
A man looking off into the distance.

How does the test work?

First, we analyze your tumor tissue to create a personalized profile around your cancer’s unique DNA. Then we look for fragments of that DNA in your blood to find out if your cancer is still present or if it is more likely to recur.

Have questions?

Call us at +1 888-662-6897.

References and footnotes

  1. Diergaarde B, Young G, Hall DW, Mazloom A, Costa G, Subramaniam S, Palomares M, Garces J, Baehner FL, Schoen RE; and other members of the Exact Sciences MRD Group. Circulating tumor DNA as a marker of recurrence risk in Stage III colorectal cancer: The α‐CORRECT study. Journal of Surgical Oncology.
  2. Centers for Medicare & Medicaid Services, Medicare Coverage Database. LCD—MolDX: Minimal Residual Disease Testing for Cancer. Accessed January 21, 2025. https://www.cms.gov/
  3. Santonja et al. EMBO. 2023. https://www.embopress.org/doi/full/10.15252/emmm.202216505
  4. The test has been validated in patients with stage II-IV colorectal cancer and Exact Sciences is currently pursuing applications in additional disease ontologies.
  5. Oncodetect is not covered for immune-oncology (IO) response monitoring.
  6. Exact Sciences may change or update its program criteria at anytime, without notice. Eligibility is not guaranteed. Exact Sciences may require that a patient provide proof of financial need if their information is not already available to Exact Sciences.

Oncodetect is a trademark of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. Genomic Health Inc, is the performing and billing laboratory for insurances purposes. Exact Sciences is a registered trademark of Exact Sciences Corporation.

This test was developed, and its performance characteristics determined by Genomic Health, Inc. The Oncodetect test was clinically validated in colorectal cancer patients with stage II-IV disease. Performance characteristics may not apply in tumor types not included in this test’s clinical validation. The test has not been cleared or approved by the US Food and Drug Administration. The test has been validated as a Laboratory Developed Test per institutional and applicable CLIA regulation (CLIA# 03D2048606) and College of American Pathology (CAP# 8869063) as qualified to perform high complexity clinical laboratory testing.